Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gastrointestinal bacteria are a highly diverse group of microorganisms residing in the human gastrointestinal tract, collectively referred to as the gut microbiota or intestinal microbiota. They play vital roles in digestion, immune function, metabolism, and maintenance of gut barrier integrity. Gut bacteria can also metabolize drugs and dietary compounds, influence the risk of infections, inflammation, and chronic diseases (such as obesity, diabetes, and cancer), and communicate with other organ systems via metabolic and signaling pathways. Although modulation of gut bacteria is an area of therapeutic interest (e.g., with antibiotics, probiotics, or enzyme inhibitors), “gastrointestinal bacteria” is not a single molecular target but a community comprising hundreds of distinct bacterial species, each with individual roles and potential relevance for drug targeting or disease association.
Inhibition or modulation of bacterial enzymes (e.g., β-glucuronidase); Alteration of microbial composition via antibiotics or probiotics; Modulation of immune activity; Changes in host metabolic pathways through microbial metabolites.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut bacterium.